Sarepta Therapeutics (NASDAQ:SRPT) Now Covered by Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft initiated coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note issued to investors on Tuesday morning, MarketBeat reports. The brokerage issued a hold rating and a $136.00 price objective on the biotechnology company’s stock.

Several other equities research analysts also recently commented on SRPT. StockNews.com downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Robert W. Baird reduced their price objective on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Needham & Company LLC reissued a “buy” rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a research report on Monday, January 27th. Guggenheim boosted their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $182.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 21st. One analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $176.77.

Sarepta Therapeutics Price Performance

NASDAQ SRPT opened at $109.68 on Tuesday. Sarepta Therapeutics has a 1 year low of $102.15 and a 1 year high of $173.25. The business’s fifty day moving average is $120.49 and its two-hundred day moving average is $125.33. The stock has a market capitalization of $10.48 billion, a P/E ratio of 87.74 and a beta of 0.75. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Insider Activity

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the transaction, the director now directly owns 5,880 shares of the company’s stock, valued at $738,234. The trade was a 21.77 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the sale, the director now directly owns 22,840 shares of the company’s stock, valued at $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

Large investors have recently bought and sold shares of the stock. Prudential Financial Inc. increased its holdings in shares of Sarepta Therapeutics by 14.7% during the 4th quarter. Prudential Financial Inc. now owns 27,965 shares of the biotechnology company’s stock worth $3,400,000 after purchasing an additional 3,574 shares during the period. Emerald Advisers LLC grew its position in Sarepta Therapeutics by 58.8% during the fourth quarter. Emerald Advisers LLC now owns 13,242 shares of the biotechnology company’s stock worth $1,610,000 after buying an additional 4,904 shares in the last quarter. Vanguard Group Inc. increased its stake in Sarepta Therapeutics by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company’s stock valued at $1,104,701,000 after acquiring an additional 117,904 shares during the period. LPL Financial LLC raised its holdings in Sarepta Therapeutics by 12.4% in the 4th quarter. LPL Financial LLC now owns 53,438 shares of the biotechnology company’s stock valued at $6,497,000 after acquiring an additional 5,895 shares in the last quarter. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of Sarepta Therapeutics in the 4th quarter worth approximately $2,164,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.